Arcturus Therapeutics (ARCT) Tops Q4 EPS by 63c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q4 EPS of ($0.32), $0.63 better than the analyst estimate of ($0.95). Revenue for the quarter came in at $33.99 million versus the consensus estimate of $42.54 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Hesai Group (HSAI) Tops Q1 EPS by 8c
• GLJ Research on Sell Rated Tesla (TSLA): 'We now see FSD as the main reason TSLA’s stock will bleed lower this year'